Company Overview
About Reify Health
Reify Health is a clinical trial acceleration company whose two platform arms — OneStudyTeam and Care Access — address the two biggest friction points in clinical research: site operations efficiency and patient enrollment reach. OneStudyTeam provides workflow software that automates the administrative burden on clinical research sites, enabling faster startup, better sponsor-site collaboration, and compliant data capture throughout trial execution. Care Access operates a decentralized clinical trial infrastructure that brings research directly to patients in underserved communities, expanding the diversity and geographic reach of clinical study populations.
Business Model & Competitive Advantage
Founded in 2017 and headquartered in Boston, Massachusetts, Reify Health has raised over $407 million in total funding, including a $220 million Series D in April 2022 co-led by Altimeter Capital and Coatue at a valuation of $4.8 billion. Other investors include ICONIQ Growth, Adams Street Partners, Dragoneer Investment Group, and Battery Ventures. The company's two back-to-back $220 million rounds (Series C and Series D within a single year) reflected strong investor conviction in the critical infrastructure role Reify plays in accelerating drug development timelines — a market where each day of delay in a Phase III trial can cost a pharmaceutical sponsor millions of dollars.
Competitive Landscape 2025–2026
Reify Health's diversity and inclusion initiative, BRIDGE, targets the persistent underrepresentation of minority groups in clinical trials — a structural problem that limits the generalizability of drug data and has historically disadvantaged non-white patient populations in pharmaceutical development. By embedding Care Access's community-based research sites and decentralized trial capabilities alongside OneStudyTeam's operational software, Reify provides a comprehensive solution that spans from study design through patient enrollment and site management, making it a strategic partner for major pharmaceutical companies and contract research organizations seeking faster and more representative trial execution.
Key Differentiators
Strong Challenger
Reify Health is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Compare Reify Health with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Reify Health? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Reify Health Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Reify Health vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →